



NCRI

National  
Cancer  
Research  
Institute

cancer c<sup>o</sup>nference  
**ncri**  
national cancer research institute

# CONFERENCE PROGRAMME

for the Second NCRI Cancer Conference  
8 - 11 October 2006 Birmingham UK

# Event Programme

Sunday 8 October

13.00 – 15.10

Workshop

14.00 – 15.00

**Mission possible: how we can beat cancer - Public Lecture**

**Fran Balkwill**

Barts and The London, Queen Mary's School of Medicine and Dentistry, London, UK

15.15 – 15.30

**Welcome Address**

**Mike Richards**

NCRI Chairman

15.30 – 16.10

**Kaposi sarcoma: model of oncogenesis - The BACR Tom Connors Lecture**

**Chris Boshoff**

Wolfson Institute for Biomedical Research, University College London, UK



16.10 – 16.50

**Clinical development of targeted molecular therapies in cancer: challenges and opportunities - The Institute of Cancer Research Lecture**

**Elizabeth A Eisenhauer**

National Cancer Institute of Canada, Queen's University, Canada



16.50 – 17.20

Break

17.20 – 18.00

**Integrating palliative care into routine cancer care: impact on clinical and financial outcomes - The Macmillan Cancer Support Lecture**

**Thomas J Smith**

Massey Cancer Center, Virginia Commonwealth University, USA



18.00 – 19.00

**Clinical Trials Showcase -  
Sponsored by Clinox Ltd**



**First mature analysis of the Intergroup  
Exemestane Study**

**Judith M Bliss**

Institute of Cancer Research, Sutton, UK

**Short course pre-operative  
radiotherapy is superior to a policy of  
selective post-operative  
chemoradiotherapy for resectable  
rectal cancer: preliminary results of the  
MRC CR07 trial**

**David Sebag-Montefiore**

NCRI and MRC Clinical Trial Unit, London, UK

**Inhibition of androgen synthesis by an  
oral, irreversible, inhibitor of  
CYP450c17 is safe and results in a  
high, durable, response rate in  
castration refractory prostate cancer  
(CRPC) patients**

**Johann S de Bono**

Institute of Cancer Research and Royal Marsden  
Hospital, Sutton, UK

19.00 – 21:00

Opening Reception and Trade Exhibition

**Monday 9 October**

08.00 – 08.50

BACR Educational Workshop – Cancer  
drug discovery



09.00 – 09.10

**Introduction to the Programme**

**Alan Ashworth**

Programme Planning Committee Chairman

09.10 – 09.50

**Dissecting tumour suppressor gene  
networks *in vivo* - The Paterson  
Institute for Cancer Research Lecture**

**Scott W Lowe**

Watson School of Biological Sciences, Cold Spring  
Harbor Laboratory, USA



09.50 – 10.30

**Transcriptional programming in normal and leukaemic stem and progenitor cells - The Leukaemia Research Fund Lecture**

**Tariq Enver**

Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK



10.30 – 11.10

Break  
Exhibition Viewing

11.10 – 11.50

**Lifestyle approaches to breast cancer risk reduction: insights and opportunities - The Breakthrough Generations Lecture**

**Leslie Bernstein**

Keck School of Medicine, University of Southern California, USA



11.50 – 12.30

**Marketing: mentor or menace? - The Economic and Social Research Council Lecture**

**Gerard Hastings**

Institute for Social Marketing and Centre for Tobacco Control Research, University of Stirling and Open University, UK



12.30 – 15.00

Lunch  
Poster Session and Exhibition Viewing

13.00 – 14.00

Commercial Workshop  
Sponsored by Bayer HealthCare



14.00 – 15.00

Careers/Mentoring/Grant Writing Workshops

15.15 – 17.30

Parallel Sessions

17.30 – 18.00

Break

18.00 – 18.40

**Winning the war against paediatric brain tumours: a fresh look at the enemy - The CR-UK London Research Institute Lecture**

**Richard Gilbertson**

St Jude Children's Research Hospital, Memphis, USA



18.40 – 19.20

**How telomeres tame the DNA damage response - The Beatson Institute for Cancer Research Lecture**

**Titia de Lange**

Rockefeller University, New York, USA



19.30 – 21.00

Civic Reception  
Sponsored by AstraZeneca

Poster Session



**Tuesday 10 October**

08.00 – 08.50

BACR Educational Workshop –Imaging of cancer targets



09.00 – 09.40

**Role of stem cells and differentiated cells in the genesis of squamous cell carcinoma - The AstraZeneca Lecture**

**Fiona Watt**

CR-UK London Research Institute, UK



09.40 – 10.20

**Why we need patient recorded outcomes (PROs) to properly evaluate cancer therapy - The IBM Lecture**

**Lesley Fallowfield**

Brighton and Sussex Medical School, University of Sussex, UK



10.20 – 11.00

Break  
Exhibition Viewing

11.00 – 11.40

**Radiation oncology in evolution: from empirical to targeted therapy - The Ludwig Institute for Cancer Research Lecture**

**W Gillies McKenna**

Institute for Radiation Biology Research, University of Oxford, UK



11.40 – 12.20

**Selecting lung cancer patients for EGFR targeted therapies - The Cancer Research Technology Lecture**

**Kenneth Hillan**

Genentech, Inc., San Francisco, USA



**12.20 – 15.00** Lunch  
Poster Session and Exhibition Viewing

**13.00 – 14.00** Commercial Workshop  
Sponsored by Affymetrix



**14.00 – 15.00** Careers/Mentoring/Grant Writing  
Workshops

**15.15 – 17.30** Parallel Sessions

**17.30 – 18.00** Break

**18.00 – 18.40** **Controlling cancer: a whole systems approach - The CR-UK Cambridge Research Institute Lecture**



**Harry Burns**

Chief Medical Officer for Scotland, St Andrew's House, Edinburgh, UK

**18.40 – 19.20** **Modelling lung cancer in the mouse - The Cancer Research UK Lecture**



**Tyler Jacks**

MIT Center for Cancer Research, Massachusetts Institute of Technology, USA

**20.00 – 20.30** Drinks Reception

**20.30 – 02.00** Conference Dinner and Party  
Sponsored by Novartis Pharmaceuticals UK Limited and Roche



## Wednesday 11 October

**09.00 – 12.15** Parallel Sessions

**12.15 – 13.00** Packed Lunch available

**13.00 – 15.00** Thrombosis and cancer workshop

# Parallel Sessions

Monday 9 October 2006

## **Breast cancer – Sponsored by AstraZeneca**

Hosted by Rob Coleman

University of Sheffield, Weston Park Hospital, UK



- **David Reid**  
University of Aberdeen, UK  
Breast cancer treatment induced bone loss (CTIBL): a draft prevention protocol
- **Andrew Tutt**  
Breakthrough Breast Cancer Research Centre, London, UK  
Triple negative breast cancer: how should we manage this 'new' disease?
- **Stephen Johnston**  
Royal Marsden Hospital, London, UK  
Recent progress with novel targeted therapies for breast cancer
- **J M Cuzick – Proffered Paper Presentation**  
Queen Mary University of London, UK  
Use of aromatase inhibitors for breast cancer prevention: rationale and current status of IBIS-II
- **A Downing – Proffered Paper Presentation**  
University of Leeds, UK  
Survival from breast cancer: the effects of social deprivation and other prognostic factors
- **M Verril – Proffered Paper Presentation**  
University of Newcastle, UK  
Anglo-Celtic IV: an NCRN randomised phase 3 trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer

## **Demonstrating value: patients in cancer research**

Hosted by Roger Wilson

NCRI Consumer Liaison Group, UK

- **Roger Wilson**  
NCRI Consumer Liaison Group, UK  
The NCRI Consumer Liaison Group - partnership is dynamic
- **Deborah Collyar**  
Patient Advocates in Research, National Cancer Institute, USA  
Patient advocates in research: transforming medical research into better results for people
- **Norman Scherzer**  
The Life Raft Group, USA  
Patient-led research

- **John Sitzia**  
Worthing and Southlands Hospital Trust, UK  
Consumer involvement in cancer research networks: findings from a formative evaluation of the Consumer Research Panels pilot project

## Diet and cancer

Hosted by Sheila Bingham

MRC Dunn Human Nutrition Unit, UK

- **Elio Riboli**  
Imperial College London, UK  
Obesity and the metabolic syndrome: the EPIC study
- **Arthur Schatzkin**  
National Cancer Institute, USA  
Dietary fat and breast cancer: new life for an old hypothesis
- **Sheila Bingham**  
MRC Centre for Nutrition in Cancer Epidemiology Prevention and Survival and MRC Dunn Human Nutrition Unit, Cambridge, UK  
Diet and colorectal cancer: epidemiology and mechanisms
- **B E Foreman – Proffered Paper Presentation**  
University of Leicester, UK  
Effect of the spice constituent Curcumin on G<sub>2</sub>/M cell cycle-related proteins

## Epigenetics and methylation

Hosted by Wolf Reik

Babraham Institute, Cambridge, UK

- **Wolf Reik**  
Babraham Institute, Cambridge, UK  
Molecular mechanisms of epigenetic reprogramming in mammalian development
- **Joseph Costello**  
University of California, San Francisco, USA  
Genome-epigenome interactions in human tumourigenesis
- **Robert Brown**  
CR-UK Beatson Laboratories, University of Glasgow, UK  
CpG island DNA methylation profiling and modulation of drug resistance by epigenetic therapies
- **Susan Clark**  
Garvan Institute of Medical Research, Sydney, Australia  
Epigenetic silent neighbourhoods in cancer cells
- **I Stancheva – Proffered Paper Presentation**  
Wellcome Trust Centre for Cell Biology, University of Edinburgh, UK  
Regulation of epigenetic gene silencing by SUMO and PIAS proteins



## Haemato-oncology – Sponsored by Novartis Pharmaceuticals UK Limited



Hosted by Bryan Young

Barts and The University of London School of Medicine and Dentistry, UK

- **Peter Valk**  
Erasmus University Medical Center, Rotterdam, The Netherlands  
Genome-wide approaches to define new genetic identities in acute myeloid leukaemia
- **Bryan Young**  
Barts and The University of London School of Medicine and Dentistry, UK  
The application of large scale genotype analysis to acute myeloid leukaemia
- **Gareth Morgan**  
Institute of Cancer Research, Sutton, UK  
Integration of global SNP-based mapping and expression arrays reveals key mechanisms and genes important in the pathogenesis of multiple myeloma
- **John Gribben**  
Barts and The University of London School of Medicine and Dentistry, UK  
Transcriptional consequences of B cell receptor cross-linking in healthy and malignant B cells

## High throughput SNP screening for the identification of cancer genes – Sponsored by Illumina



Hosted by Malcolm Dunlop

MRC Human Genetics Unit, UK

- **Rhian Gwilliam**  
The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK  
Scanning the genome for genetic determinants of complex traits
- **Malcolm Dunlop**  
MRC Human Genetics Unit, Western General Hospital, Edinburgh, UK  
Mapping complex traits in colorectal cancer
- **Paul Pharoah**  
CR-UK Department of Oncology, Strangeways Research Laboratory, Cambridge, UK  
A genome-wide association study in breast cancer
- **David L Barker**  
Illumina Inc., San Diego, USA  
Human cancer cells, normal adult cells, somatic stem cells and embryonic stem cells have distinct DNA methylation signatures
- **Panel discussion**

## Imaging

Hosted by Eric Aboagye

Imperial College School of Medicine, UK

- **David Piwnica-Worms**  
Washington University School of Medicine, USA  
Spying on cancer with genetically encoded imaging reporters
- **Eric Aboagye**  
Hammersmith Hospital, Imperial College London, UK  
*In vivo* imaging of targeted therapies by positron emission tomography
- **Anwar Padhani**  
Mount Vernon Hospital, Northwood, Middlesex, UK  
MRI in pre-clinical and clinical trials of anti-vascular treatments
- **V R Bulusu – Proffered Paper Presentation**  
Addenbrookes Hospital, Cambridge, UK  
Size does not matter! Patterns of response and progression in patients (pts) with inoperable and metastatic gastro intestinal stromal tumours (GISTS) on imatinib mesylate (IM)

## NCRI Clinical Study Group – Colorectal cancer

Hosted by John Scholefield

University Hospital Nottingham, UK

- **John Scholefield**  
University Hospital Nottingham, UK  
Welcome and introduction
- **Seizing the research opportunities of the National Screening Programme for bowel cancer:**  
**Bob Steele**  
University of Dundee, UK  
The programme and the clinical research opportunities
- **Ian Tomlinson**  
CR-UK London Research Institute, UK  
Genetic opportunities  
Comments, questions and discussion
- **Translational research: predictive markers for therapy**  
**David Kerr**  
University of Oxford, UK  
Predicting benefit from adjuvant therapy: QUASAR and QUASAR2
- **Matt Seymour**  
University of Leeds, UK  
Predicting response to chemotherapy: lessons from FOCUS
- **Tim Maughan**  
Wales Cancer Trials Network, Section of Clinical Oncology, Velindre Hospital, Cardiff, UK  
Predicting response to EGFR therapy: the COIN, PICCOLO, XERXES and New Epoch trials  
Comments, questions and discussion

- **Surgical studies:**
  - **Bob Steele/John Monson**  
University of Dundee, UK/ Academic Surgical Unit, Castle Hill Hospital, Cottingham, Hull, UK  
The quality of surgery in the CR07 trial
  - **Dion Morton**  
University of Birmingham, UK  
New trials in surgical therapy: e.g. FOXTROT

## **NCRI Clinical Study Group – Head and neck cancer**

Hosted by Martin Robinson

Weston Park Hospital, UK

- **Chris Boshoff**  
Wolfson Institute for Biomedical Research, University College London, UK  
New agents
- **Jayne Franklin**  
University of Birmingham, UK  
Thyroid trials
- **Chris Nutting**  
Institute of Cancer Research, Royal Marsden Hospital, London, UK  
Radiotherapy studies
- **Martin Birchall**  
University of Liverpool, UK  
Surgical studies

## **NCRI Clinical Study Group – Lung cancer**

Hosted by Tim Eisen

University of Cambridge, UK

- **Tim Eisen**  
University of Cambridge, UK  
Overview and the trials development pathway
- **Stephen Falk**  
Bristol Oncology and Haematology Centre, UK  
Rare Tumours' Subgroup review
- **David Ferry**  
Black Country Cancer Research Network, The Royal Wolverhampton Hospitals NHS Trust, UK  
Advanced Disease Subgroup review
- **Allan Price**  
Western General Hospital, University of Edinburgh, UK  
LORD Subgroup review
- **John Field**  
University of Liverpool Cancer Research Centre, UK  
Translational Subgroup review
- **Mick Peake**  
Glenfield Hospital, University Hospitals of Leicester NHS Trust, UK  
SCEPTRE Subgroup review

- **David Waller**  
Glenfield Hospital, University Hospitals of Leicester NHS Trust, UK  
Mesothelioma Subgroup review
- **Tim Eisen**  
University of Cambridge, UK  
Discussion

## NCRI Informatics

Hosted by Richard Begent

Royal Free and University College Medical School, UK

- **Robin Clark**  
NCRI Informatics Coordination Unit, London, UK  
NCRI Informatics: How did we get here and where are we going?
- **Kenneth Buetow**  
National Cancer Institute Centre for Bioinformatics, Bethesda, USA  
The cancer Biomedical Informatics Grid (caBIG™): enabling the patient-centric molecular medicine revolution
- **Monica Jones**  
Animo Consultancy Ltd, UK  
Reducing the burden of information provision and data collection: a 21st century challenge
- **James Brenton**  
Hutchison/MRC Research Centre, Cambridge, UK  
CancerGrid: tools for tissue-based research from clinical trials
- **Phil Quirke**  
University of Leeds, UK  
Twenty first century clinical trials - a multidisciplinary approach
- **P D Lewis – Proffered Paper Presentation**  
Swansea University, UK  
Mining cancer: data analysis needs standards too

## Paediatric oncology – Translational biology

Hosted by Andy Pearson

Institute of Cancer Research, Royal Marsden Hospital, UK

- **Richard Gilbertson**  
St Jude's Children's Research Hospital, Memphis, USA  
Translational biology and paediatric neuro-oncology: old news to deaf ears?
- **Janet Shipley**  
Institute of Cancer Research, Sutton, UK  
Significance of specific genomic amplification events in rhabdomyosarcomas
- **Sten Eirik W Jacobsen**  
Lund Stem Cell Center, Lund University, Sweden  
Identity and cellular origin of leukaemic stem cells

- **Frank Speleman**  
Center for Medical Genetics, Ghent University Hospital, Belgium  
New therapy concepts for neuroblastoma: successful *in vitro* results with small-molecule MDM2 antagonist nutlin-3 and the search for new molecular targets using genome wide analysis of tumour cells and foetal neuroblasts
- **Rachael Natrajan – Proffered Paper Presentation**  
Institute of Cancer Research, UK  
Blastemal expression of IGF1R in Wilms tumours is driven by increased copy number and correlates with relapse

### Promoting early presentation of cancer

Hosted by Amanda Ramirez

St Thomas' Hospital, Adamson Centre for Mental Health, UK

- **Jane Wardle**  
University College London, UK  
Improving uptake of cancer screening
- **Amanda Ramirez**  
St Thomas' Hospital, Adamson Centre for Mental Health, Institute of Psychiatry/Kings College London, UK  
Promoting early presentation of breast cancer
- **Lisa Cohen**  
West of Scotland Cancer Awareness Project, University of Strathclyde, UK  
Spreading the word about mouth cancer

### Targeting DNA damage and repair for new drug discovery

Hosted by Michelle Garrett

Institute of Cancer Research, Sutton, UK

- **Thomas Helleday – The BACR AstraZeneca Frank Rose Young Scientist Award Lecture**  
Institute for Cancer Studies, University of Sheffield, UK  
DNA replication repair: from molecular insights towards new approaches to anti-cancer therapy
- **Johann de Bono**  
Institute of Cancer Research, Sutton, UK  
A first in man Phase I trial involving biologic endpoints of the oral small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours with and without *BRCA* mutation
- **Roger Griffin**  
Northern Institute for Cancer Research, University of Newcastle upon Tyne, UK  
DNA damage-activated kinases as targets for cancer therapy
- **H D Thomas – Proffered Paper Presentation**  
Northern Institute for Cancer Research, University of Newcastle upon Tyne, UK  
Preclinical selection of a PARP inhibitor for clinical trial

## Tumour cell migration and invasion

Hosted by Margaret Frame

Beatson Institute for Cancer Research, Glasgow, UK

- **Margaret Frame**  
Beatson Institute for Cancer Research, Glasgow, UK  
New functions of focal adhesion kinase; defining its role in cancer development and a new function for the FERM domain
- **Inke Näthke**  
University of Dundee, UK  
Cytoskeletal regulation in cell migration by the adenomatous polyposis coli protein
- **Owen Sansom**  
Beatson Institute for Cancer Research, Glasgow, UK  
*c-Myc* deletion and *K-Ras* activation modify cell migration and invasion of *Apc* deficient cells *in vivo*
- **Eduard Batlle**  
Institute for Research in Biomedicine, Barcelona, Spain  
Epithelial cell sorting and colorectal cancer suppression through EphB-ephrinB interactions
- **Albert Reynolds**  
Vanderbilt University School of Medicine, Nashville, USA  
Novel roles for p120 in Rac-dependant inhibition of Rho and in contact inhibition of cell growth
- **J Sturge - Proffered Paper Presentation**  
Imperial College London, UK  
Recycling endosomes generate localized Rho-ROCK-MLC2-based contractile signals via Endo180 to promote adhesion disassembly during tumour cell migration

Tuesday 10 October 2006

## Advances in upper GI cancer

Hosted by John Neoptolemos

Royal Liverpool University Hospital, UK

- **Max Bachem**  
University of Ulm, Germany  
On the role of stellate cells in pancreas cancer
- **Rebecca Fitzgerald**  
Hutchison/MRC Research Centre, Cambridge, UK  
Screening and surveillance for upper GI neoplasia
- **Michael Goggins**  
The Johns Hopkins Medical Institutions, Baltimore, USA  
Molecular markers of pancreatic neoplasia

- **A Sultana - Proffered Paper Presentation**  
University of Liverpool, UK  
Meta-analysis of the management of locally advanced and metastatic pancreatic cancer
- **P Monaghan - Proffered Paper Presentation**  
Cancer Epidemiology and Prevention Research Group, Department of Epidemiology, Queen's University, Belfast, UK  
Factors influencing entry into routine surveillance for patients with Barrett's Oesophagus: the Northern Ireland Barrett's Oesophagus Register

### Behaviour change for cancer prevention

Hosted by Jane Wardle

University College London, UK

- **Robert West**  
CR-UK Health Behaviour Unit, University College London, UK  
How can the UK possibly get its smoking prevalence below 20%?
- **Victor J Strecher**  
University of Michigan Comprehensive Cancer Center, USA  
Cancer prevention and the internet
- **Greg Beales**  
Cabinet Office, London, UK  
Personal responsibility and behaviour change
- **T Coleman – Proffered Paper Presentation**  
University of Nottingham, UK  
Impact of contractual financial incentives on the ascertainment and management of smoking in primary care

### Cancer genetics

Hosted by Nazneen Rahman

Institute of Cancer Research, Sutton, UK

- **Nazneen Rahman**  
Institute of Cancer Research, Sutton, UK  
DNA repair genes and breast cancer predisposition – a complex web of high and low penetrance susceptibility alleles
- **Julian Sampson**  
Institute of Medical Genetics, Cardiff University, UK  
MUTYH, base excision repair and colorectal cancer
- **Michael Stratton**  
Wellcome Trust Sanger Institute, Cambridge, UK  
The mutational landscape of human cancers

**Combined modality therapy –  
Organised by the British Oncological Association  
Hosted by Rob Coleman**



University of Sheffield, Weston Park Hospital, UK

- **Cornelis JH van de Velde and Tim S Maughan**  
Leiden University Medical Centre, The Netherlands and Velindre Hospital, Cardiff University, UK  
Is surgery all you need for rectal cancer?
- **Andrew Hayes and Martin H Robinson**  
Royal Marsden Hospital, UK and Weston Park Hospital, Sheffield, UK  
Do soft tissue sarcoma patients need one or two local treatment modalities?
- **Adrian Crellin**  
Cookridge Hospital, Leeds, UK  
One - two - three - four modalities to cure oesophageal and gastric cancer?

**DNA repair**

Hosted by Simon Boulton

CR-UK London Research Institute, UK

- **Kevin Hiom**  
MRC Laboratory of Molecular Biology, Cambridge, UK  
The molecular functions of BRCA1 in DNA repair and cancer predisposition
- **Keith Caldecott**  
Genome Damage and Stability Centre, University of Sussex, UK  
Chromosomal single-strand break repair and neurodegenerative disease
- **James Turner**  
National Institute for Medical Research, London, UK  
The role of BRCA1 in spermatogenesis
- **J D Ward - Proffered Paper Presentation**  
CR-UK London Research Institute, Clare Hall Laboratories, UK  
The role of the single *C. elegans* RAD51 paralog in repair of impeded replication forks

**Drug development: target validation and biomarkers**

Hosted by Sir David Lane

Institute of Molecular and Cell Biology, Singapore and University of Dundee, UK

- **Sir David Lane**  
Institute of Molecular and Cell Biology, Singapore and University of Dundee, UK  
Cell based screening for activators of the p53 response
- **Mark Rolfe**  
Millennium Pharmaceuticals Inc, USA  
The discovery and development of VELCADE, a novel proteasome inhibitor for cancer therapy



- **Ravi Salgia**  
University of Chicago, USA  
Role of c-Met in lung cancer
- **Eric Raymond**  
Service Inter-Hospitalier de Cancérologie Bichat-Beaujon, Hôpital Beaujon, Paris, France  
Validation of VEGFR and mTOR as molecular targets for cancer therapeutics: past history and future clinical development of sunitinib malate (SU11248) and temsirolimus (CCI-779) using molecularly oriented translational researches
- **Spiros Linardopoulos - Proffered Paper Presentation**  
Institute of Cancer Research, UK  
Aurora-A kinase inhibition downregulates NF-kappaB and sensitises human tumour cells to chemotherapeutic agents

### **NCRI Clinical Studies Development Group – Complementary therapies**

Hosted by **Susie Wilkinson**

Marie Curie Palliative care Research and Development Unit, London, UK

- **Leslie Walker**  
Institute of Rehabilitation and Oncology Health Centres, University of Hull/Hull and East Yorkshire Hospitals NHS Trust, UK  
A randomised controlled trial of reflexology in women with early stage breast cancer
- **Alexander Molassiotis**  
University of Manchester, UK  
Managing cancer-related fatigue with acupuncture: a pilot randomised trial
- **Debbie Sharp and Maggie Evans**  
University of Bristol, UK  
Men with cancer: is their use of complementary and alternative medicine a response to needs un-met by orthodox health care?
- **Dai Roberts and Ann Caress**  
St Anne's Hospice, Manchester, UK and University of Manchester, UK  
A multi-centre evaluation of complementary therapy provision for patients with cancer – access, expectations and indications for therapy
- **Tony Leathem**  
University College London, UK  
Effects of diet, complementary medicines and lifestyle on breast cancer progression: the DietCompLyf trial
- **Susie Wilkinson**  
Marie Curie Palliative Care Research and Development Unit, London, UK  
Conclusion

## NCRI Clinical Study Group – Lymphoma Sponsored by Roche



Hosted by Peter Johnson

CR-UK Wessex Regional Medical Oncology Unit, University of Southampton, UK

- **Andrew Jack**  
Birmingham Nuffield Hospital, UK  
New insights into the biology of large cell lymphoma
- **Michael Pfreundschuh**  
University of Saarland, Homburg, Germany  
Progress in the treatment of DLBCL: a German perspective
- **George Mikhaeel**  
Guy's and St Thomas' Hospital, London, UK  
PET imaging in the management of large cell lymphoma
- **Tim Illidge**  
Paterson Institute for Cancer Research, Manchester, UK  
Using radioimmunotherapy in large cell lymphoma

## NCRI Clinical Studies Development Group – Teenage and young adults

Hosted by Jeremy Whelan

Middlesex Hospital, University College London Hospitals NHS Trust, UK

- **Jeremy Whelan**  
Middlesex Hospital, University College London Hospitals NHS Trust, UK  
Why do we need an NCRI group for teenagers and young adults?
- **Jill Birch**  
CR-UK Paediatric and Familial Cancer Research Group, University of Manchester, UK  
The national profile of cancers in teenagers and young adults in England
- **Lorna Fern**  
NCRI Teenage and Young Adults Clinical Studies Development Group, UK  
Inclusion of teenagers and young adults in clinical trials in England – How are we doing?
- **Clare Rowntree**  
University Hospital of Wales, Cardiff, UK  
How should young adults with acute lymphoblastic leukaemia be treated?
- **Kelly Denver**  
University College London, UK  
Why hospital environments are important to teenagers and young adults
- **TYA Working parties:**  
**Michael Hawkins**  
University of Birmingham, UK  
Survivorship: patient and doctor perspectives

## **Margaret Rogers**

University of Manchester, UK

Priorities for TYA and health services research

## **Ian Lewis**

St James' University Hospital, Leeds, UK

Do we need a specialised cancer registry for TYA?

## **Ovarian cancer**

Hosted by Hani Gabra

West London Gynaecological Cancer Centre, Imperial College London, UK

- **Hani Gabra**  
West London Gynaecological Cancer Centre, Imperial College London, UK  
The WWOX gene in epithelial ovarian cancer
- **Honami Naora**  
MD Anderson Cancer Centre, University of Texas, USA  
The paradox of ovarian cancers: developmental patterning in the wrong context?
- **James Brenton**  
University of Cambridge, UK  
Functional genomics studies in ovarian cancer
- **Fran Balkwill**  
Barts and The London, Queen Mary's School of Medicine and Dentistry, London, UK  
Translating our knowledge of the cytokine network of ovarian cancer into new cancer treatments
- **M Spears - Proffered Paper Presentation**  
Cancer Research UK, University of Edinburgh Cancer Research Centre, UK  
The expression and function of LSAMP in epithelial ovarian cancer

## **Paediatric oncology – Clinical trials**

Hosted by Andy Pearson

Institute of Cancer Research, Royal Marsden Hospital, UK

- **Andy Pearson**  
Institute of Cancer Research, Royal Marsden Hospital, UK  
A new international therapeutic classification for neuroblastoma
- **Carolyn Freeman**  
McGill University, Montreal, Canada  
The Children's Oncology Group CNS studies: strategy, progress and plans for the future
- **James Nachman**  
University of Chicago Children's Hospital, USA  
Acute lymphoblastic leukaemia 2006: the COG paradigm

- **Ian Lewis**  
Leeds Teaching Hospital, UK  
EICESS-92: A successful collaborative intergroup trial in Ewing's Sarcoma with unexpected results
- **D Pang - Proffered Paper Presentation**  
University of Manchester and Cancer Research UK, Manchester, UK  
Cancer incidence in relatives of children with osteosarcomas and chondrosarcomas

### Places of care near the end of life

Hosted by Sheila Payne

University of Sheffield, UK

- **Julia Addington-Hall**  
University of Southampton, UK  
Dying at home in the UK: ideology and evidence
- **Joan Teno**  
Brown Medical School, Brown University, USA  
Bereaved family member perspectives on the last place of care in the USA
- **Philip Larkin**  
Centre for Nursing Studies, National University of Ireland, Eire  
Transition towards palliative care: an exploration of its meaning for advanced cancer patients in Europe
- **E Davies - Proffered Paper Presentation**  
King's College London, UK  
How is place of death changing and what affects it? Analysis of service and registry data
- **C J N Meystre - Proffered Paper Presentation**  
Warwick Hospital, UK  
Does poorer educational status influence engagement with a palliative care needs assessment survey sent by post to patients diagnosed with incurable lung cancer?

### Prostate cancer

Hosted by Norman Maitland

YCR Cancer Research Unit, University of York, UK

- **Charles G Drake**  
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA  
Immunotherapy for prostate cancer: clinical and basic science perspectives
- **Angus Dalglish**  
St George's Hospital Medical School, UK  
Immunotherapy and prostate cancer

- **Christian Ottensmeier**  
University of Southampton, UK  
DNA vaccination for prostate cancer: from the laboratory to the bedside
- **A Cooper - Proffered Paper Presentation**  
University of Portsmouth, UK  
Prostasomes possess properties compatible with their influencing the course of neoplastic prostate disease
- **Luke Gaughan - The BACR Translational Research Award Lecture**  
Northern Institute for Cancer Research, University of Newcastle upon Tyne, UK  
Novel mechanisms of androgen receptor regulation in prostate cancer

### Stem cells in cancer

Hosted by Rob Clarke

Christie Hospital, Manchester, UK

- **Robert Clarke**  
Christie Hospital, Manchester, UK  
Regulation of human breast stem cells
- **Anne Collins**  
Yorkshire Cancer Research Unit, University of York, UK  
 $\alpha_2^{\text{hi}}/\text{CD133}^+$  prostate cancer stem cells from human tumours are highly tumourigenic and metastatic *in vivo*
- **Maarten van Lohuizen**  
The Netherlands Cancer Institute, Amsterdam, The Netherlands  
Polycomb repressors controlling stem cell fate: implications for cancer and development
- **K L Britt – Proffered Paper Presentation**  
Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, UK and Garvan Institute of Medical Research, Sydney, Australia  
Mouse mammary epithelial stem cell lineage analysis

### Survivorship

Hosted by Nigel Palmer

NCRI Consumer Liaison Group, UK

- **Ziv Amir**  
Macmillan Research Unit, University of Manchester, UK  
Can you afford to have cancer?
- **Maggie Crowe**  
Royal United Hospital, Bath, UK  
Unidentified or unmet: what are the supportive care needs of people following cancer treatment?

- **Noreen Aziz**  
Office of Cancer Survivorship, National Cancer Institute, Bethesda, USA  
Cancer survivorship: challenges and opportunities of an evolving research area
- **A M Campbell - Proffered Paper Presentation**  
Strathclyde University, Glasgow, UK  
A randomised controlled trial of a supervised group exercise programme as a rehabilitation treatment for women receiving treatment for early stage breast cancer

## The future of UK cancer intelligence – Organised by the United Kingdom Association of Cancer Registries

Hosted by Mike Richards

National Cancer Director for England, UK



- **Henrik Møller**  
Thames Cancer Registry and Kings College London, UK  
The burden of cancer in England in 2020
- **Chris Carrigan**  
National Cancer Registry, UK  
Changing the delivery of cancer information, intelligence and informatics
- **Ken Lloyd and Sue Forsey**  
Thames Valley Cancer Network, UK  
How should we audit and monitor the delivery of cancer services?
- **David Forman**  
Northern and Yorkshire Cancer Registry and University of Leeds, UK  
Extending the uses of cancer information

## The immune system: a barrier to cancer?

Hosted by Caetano Reis e Sousa

CR-UK London Research Institute, UK

- **Adrian Hayday**  
Guy's, King's and St Thomas' School of Medicine, UK  
Helping the natural capacity of unconventional T cells to fight tumours
- **Cornelis J M Melief**  
Leiden University Medical Centre, The Netherlands  
Immunotherapy of established papilloma virus-induced (pre-)malignant lesions in mice, rabbits and patients
- **Vincenzo Cerundolo**  
Weatherall Institute of Molecular Medicine, University of Oxford, UK  
Harnessing iNKT cells in cancer vaccines

Wednesday 11 October 2006

### Addressing patients' care needs through nurse-led research

Hosted by Alison Richardson

Florence Nightingale School of Nursing and Midwifery, King's College London, UK

- **Barbara Given**  
Michigan State University, USA  
Managing cancer patients' symptoms through nurse-delivered behavioural interventions
- **Nora Kearney**  
University of Stirling, UK  
Is nursing's future remote? Advancing symptom management through the application of technology
- **Karen Cox**  
University of Nottingham, UK  
Enhancing early phase trial management: A randomised controlled trial of nurse-managed trial conclusion
- **S Faithfull - Proffered Paper Presentation**  
University of Surrey, UK  
Evaluation of a structured care telephone follow-up service for women with ovarian cancer post treatment

### Challenges in diagnosis and prevention of cancer in primary care

Hosted by Janet Darbyshire and Mike Richards

MRC Clinical trials Unit, London, UK and National Cancer Director, St Thomas' Hospital, UK

- **Una Macleod**  
University of Glasgow, UK  
Pre-hospital delay in cancer diagnosis: what can we learn from the literature?
- **Kurt Stange**  
Case Western Reserve University, USA  
Cancer prevention among the competing demands and opportunities of primary care
- **David Weller**  
University of Edinburgh, UK  
Promoting earlier diagnosis of cancer in primary care
- **Willie Hamilton**  
University of Bristol, UK  
The CAPER studies

## Chemical biology in relation to cancer

Hosted by Stephen Neidle and Roger Griffin

University of London, UK and University of Newcastle upon Tyne, UK

- **Tarun Kapoor**  
Rockefeller University, USA  
Using kinase inhibitors to probe cell division mechanisms
- **Hagan Bayley**  
University of Oxford, UK  
Prospects for rapid sequencing of large genomes
- **Rodolfo Marquez**  
University of Dundee, UK  
Biological chemistry approaches to the synthesis of PDK1 and PKB inhibitors
- **Stephen Neidle**  
University of London, UK  
The chemical biology of telomere targeting agents
- **Ian Collins**  
CR-UK Centre for Cancer Therapeutics, Institute of Cancer Research, UK  
Combinatorial and structure-based approaches to the discovery of new inhibitors of PKB

## Chemoprevention

Hosted by Andy Gescher

University of Leicester, UK

- **James Crowell**  
National Cancer Institute, Bethesda, USA  
Identifying and developing novel, new chemopreventive agents
- **Fritz H Schröder**  
Erasmus Medical Centre, Rotterdam, The Netherlands  
Chemoprevention in prostate cancer - results of phase II studies and growth inhibition in nude mice
- **Maggie Manson**  
University of Leicester, UK  
The potential for dietary agents in cancer prevention and therapy
- **R Lal - Proffered Paper Presentation**  
CR-UK London Research Institute, UK  
Prevention of MEK1-activated tumour formation by immunosuppression of the host microenvironment



## Colorectal cancer

Hosted by Alan Clarke

Cardiff University, UK

- **Ian Tomlinson**  
CR-UK London Research Institute, UK  
Loss of heterozygosity in human and mouse colorectal tumours
- **Alan Clarke**  
Cardiff University, UK  
Investigating early neoplastic changes in the intestine through conditional deletion in the mouse
- **Riccardo Fodde**  
Erasmus University Medical Center, The Netherlands  
Stemness, signal transduction and genetic instability in intestinal cancer: new bottle, old wine
- **G Smith - Proffered Paper Presentation**  
University of Dundee, Scotland, UK  
K-Ras mutations define a distinct genetic pathway to colorectal cancer, associated with reduced patient survival
- **W Kolch - Proffered Paper Presentation**  
Beatson Institute for Cancer Research, Glasgow, UK  
RKIP expression in colorectal cancer predicts metastatic recurrence and overall survival

## CR-UK Development Committee workshop – Sponsored by Cancer Research UK

Hosted by Herbie Newell

Cancer Research UK, UK



- **Clive Stanway**  
Wolfson Institute, University College London, UK  
The CRT Development Labs and their role in the Development Committee
- **Steve Wedge**  
AstraZeneca, UK  
Current challenges in identifying and developing small molecule cancer therapeutics
- **Michelle Garrett,**  
CR-UK Centre for Cancer Therapeutics, Institute of Cancer Research, UK  
What makes a good drug target and the drug development process
- **Caroline Dive**  
Cellular and Molecular Pharmacology Group, Paterson Institute for Cancer Research, Manchester, UK  
When should I apply to the Development Committee for funding?'

- **Workshop panel**

How to successfully apply for a Development Committee grant  
Dummy applicants: Herbie Newell and Business Manager  
'Example of a bad DC proposal'; Tony Raynham, Tony  
Raynham and Business Manager 'Example of a good DC  
proposal'

Panel: Caroline Dive (Chair), Michael Olson, Peter Fischer,  
Clive Stanway, Phil L'Huilier

## Future directions in oncology imaging - Sponsored by The Royal College of Radiologists

Hosted by Rodney Reznick

Institute of Cancer, Barts and the London, UK



- **Lawrence Schwartz**

Memorial Sloan-Kettering Cancer Center, USA

Imaging as a biomarker: emerging roles and challenges

- **Rodney Reznick**

Institute of Cancer, Barts and the London, UK

Pelvic cancer: How MRI helps to develop new treatments

- **Anwar Padhani**

Mount Vernon Hospital, UK

Angiogenesis imaging and tumour response

- **Laura M Kenny – ACP McElwain Prize Lecture**

Imperial College London, UK

[<sup>18</sup>F]Fluorothymidine positron emission tomography - a novel  
method to study cell proliferation *in vivo*

## Immunotherapy

Hosted by Christian Ottensmeier

University of Southampton, UK



- **Iacob Mathiesen**

Inovio AS, Norway

Gene delivery by electroporation: applications for immune  
therapy

- **Hans Stauss**

Royal Free Hospital, University College London, UK

Mechanisms of impaired T cell responses against tumour-  
associated antigens

- **Ugur Sahin**

Johannes Gutenberg University, Germany

A pharmacological approach for the development of new  
recombinant vaccines

- **J G Chai - Proffered Paper Presentation**

Imperial College London, UK

Strategies for overcoming naturally occurring  
unresponsiveness to HY in CBA mice

- **E J Cheadle - Proffered Paper Presentation**  
Paterson Institute for Cancer Research, Manchester, UK  
Therapeutic efficacy of engineered T cells targeting CD19 in a B-cell lymphoma model
- **J C Gray - Proffered Paper Presentation**  
University of Southampton, UK  
Overcoming tolerance with combinations of immunostimulatory monoclonal antibodies

## Infection and cancer – Supported by an unrestricted educational grant from GlaxoSmithKline

Hosted by Lawrence Young

CR-UK Institute for Cancer Studies, University of Birmingham, UK



- **Lawrence Young**  
CR-UK Institute for Cancer Studies, University of Birmingham, UK  
EBV and cellular transformation: modulation of cytokine and cell signalling pathways to promote virus persistence and oncogenesis
- **Richard Longnecker**  
Northwestern Medical School, Chicago, USA  
How to enter B and epithelial cells: lessons from Epstein-Barr virus
- **Dennis J McCance**  
Centre for Cancer Research and Cell Biology, Queen's University, UK  
AKT - a therapeutic target for epithelial cancers caused by HPV
- **David Blackburn**  
CR-UK Institute for Cancer Studies, University of Birmingham, UK  
KSHV immune modulation and the evolution of a potential anti-inflammatory therapeutic
- **M Vockerodt – Proffered Paper Presentation**  
Cancer Research UK Institute for Cancer Studies, University of Birmingham, UK  
The EBV-encoded latent membrane protein-1 imposes a Hodgkin/Reed-Sternberg-like gene expression signature when expressed in germinal centre B cells
- **M S Campo – Proffered Paper Presentation**  
Institute of Comparative Medicine, University of Glasgow, UK  
Papillomavirus E5 proteins and MHC class I: a common way to evade the immune response

## Lung cancer

Hosted by John Field

University of Liverpool Cancer Research Centre, UK

- **James Mulshine**  
Rush University Medical Centre, Chicago, USA  
Update on early lung cancer management

- **John Field**  
University of Liverpool Cancer Research Centre, UK  
Developing a molecular epidemiological risk prediction model
- **Paolo Boffetta**  
International Agency for Cancer Research, Lyon, France  
Lung cancer due to occupational exposures
- **M Linch - Proffered Paper Presentation**  
Royal Marsden Hospital, Sutton, Surrey, UK  
An audit of the use of pemetrexed for the treatment of malignant pleural mesothelioma in an expanded access programme compared to previous experience with MVP (mitomycin C, vinblastine and cisplatin)
- **G M Jacobson - Proffered Paper Presentation**  
University of Liverpool, UK  
Downregulation of REST/NRSF induces transcription of multiple genes in lung cancer that may contribute to tumour phenotype and provide markers for clinical disease
- **A Alzetani - Proffered Paper Presentation**  
Heart of England NHS Trust, Birmingham, UK  
Serum proteomics in lung cancer

## **NCRI Clinical Studies Development Group – Psychosocial Oncology**

Hosted by Mike Baum

University College London, UK

- **Mike Baum**  
University College London, UK  
Introduction and The remit of the Group and its subgroups
- **Julia Brown**  
University of Leeds, UK  
Quality of life aspects of big trials
- **Penny Hopwood**  
Christie Hospital NHS Trust, Manchester, UK  
Quality of life data from START and TACT trials
- **Elaine Rankin**  
Ninewells Hospital, Dundee, UK  
Local research in Dundee
- **Louise Jones**  
Marie Curie Palliative Care Research Unit, London, UK  
Local research in London/at the Royal Free
- **Galina Velikova**  
CR -UK Clinical Centre, University of Leeds, UK  
The development and funding of a particular study
- **Noreen Aziz**  
Office of Cancer Survivorship, National Cancer Institute, USA  
Cancer survivorship, lifestyle interventions and the teachable moment

## Radiobiology – Sponsored by the British Oncological Association

Hosted by Penny Jeggo

Genome Damage and Stability Centre, University of Sussex, UK



- **Penny Jeggo**  
Genome Damage and Stability Centre, University of Sussex, UK  
Essential role of non-homologous end-joining in the maintenance of haematopoietic stem cell function
- **Katherine Vallis**  
Princess Margaret Hospital, Toronto, Canada  
Molecule guided radiation therapy
- **Rob Coppes**  
University of Groningen, The Netherlands  
Stem cell therapy to reduce radiation-induced toxicity
- **Gillian Tozer**  
University of Sheffield, UK  
Imaging tumour vascular morphology and function for assessing therapeutic efficacy
- **K M Prise - Proffered Paper Presentation**  
Gray Cancer Institute, Northwood, UK  
Cytokine-dependent cell signalling in response to targeted irradiation
- **S P Wheatley - Proffered Paper Presentation**  
University of Sussex, UK  
Separating the anti-apoptotic and mitotic roles of survivin

## Research information for patients and the public

Hosted by Derek Stewart

NCRI Consumer Liaison Group, UK

- **Matthew Hallsworth**  
UK Clinical Research Collaboration, UK  
Public awareness of clinical research
- **R Owen – Proffered Paper Presentation**  
3 Counties Cancer Network, Gloucestershire, UK  
Deciding whether to take part in cancer clinical trials: patient and staff perspectives
- **Jessica Corner, Claire Dawson, Karen Poole and members of the NCRI CLG**  
Macmillan Cancer Relief, UK; Institute of Cancer Research, Sutton, UK; Surrey, West Sussex and Hampshire Cancer Research Network, UK and NCRI Consumer Liaison Group, UK  
Patients in research - sharing information and resources
- **Richard Stephens**  
NCRI Consumer Liaison Group, UK  
Patient information sheets

## Tissue banks

Hosted by Brian Clark

onCoreUK, London, UK

- **Brian Clark**  
onCoreUK, London, UK  
Biosample and information banking for cancer research
- **Manuel Morente**  
Spanish National Tumour Bank Network, Madrid, Spain  
Tumour bank networking: the Spanish design
- **Peter Riegman**  
Erasmus Medical Centre Tissue Bank, Rotterdam, The Netherlands  
Creating TuBaFrost: a European human frozen tumour tissue bank
- **Sandy Mather**  
Human Tissue Authority, London, UK  
Establishing a regulatory, advisory and licensing environment to foster research tissue banking
- **G T Thomas - Proffered Paper Presentation**  
South West Wales Cancer Institute, Swansea, UK  
Quality assurance in a regional population based tumour bank

# Workshops

Sunday 8 October 2006

## **Cancer Recognised Research Group (RRG) workshop on molecular mechanisms of metastasis**

13:00 – 15.10

Hosted by Charles Campbell and Stephanie McKeown

Queen's University Belfast, UK and University of Ulster, UK

- **Philip Rudland**  
The University of Liverpool, UK  
Keynote Lecture - Molecular mechanisms of metastasis
- **A H Devlin**  
Biomedical Science, University of Ulster, Coleraine, UK  
Expression of Cytochrome P450 1B1 protein in tumours: role of translational control
- **E A Dunlop**  
Haematology Research Group, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK  
Evidence of abnormal erythropoietin receptor downregulation in non-small cell lung carcinoma
- **G Collett**  
Department of Surgery, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK  
Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells
- **H Xu**  
Department of Surgery, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK  
Ligand-activated vitamin D receptor (VDR) modulates the neoplastic phenotype through osteopontin (OPN) and  $\beta$ -Catenin/LEF-1/TCF signalling
- General discussion
- Tea/Coffee

Monday 9 October 2006

## **BACR educational workshop - Cancer drug discovery**

08.00 – 08.50

- **Michelle Garrett**  
Institute of Cancer Research, Sutton, UK
- **Andrew Westwell**  
Cardiff University, UK



## Commercial workshop

### A brave new world: the opportunity and practicality of targeted therapy in renal cell cancer and beyond

Sponsored by Bayer HealthCare

13:00 - 14:00

- **Tim Eisen**  
University of Cambridge, UK  
Tyrosine Kinase Inhibitors in 2006 - state of play
- **Aslam Sohaib**  
Institute of Cancer Research and Royal Marsden Hospital, London, UK  
How Should We Measure Efficacy of Tyrosine Kinase Inhibitors - is RESIST enough?
- **Kim Edmonds**  
Royal Marsden Hospital, London, UK  
Practicalities and Management - real life experience
- **Paul Nathan**  
Mount Vernon Cancer Centre, London, UK  
Future Directions - What questions remain?



## Clinical Fellows' careers workshop

14.00 – 15.00

Hosted by Nick Lemoine

Barts and The London School of Medicine and Dentistry, UK

- **Alan Melcher**  
CR-UK Clinical Centre, St James' University Hospital, University of Leeds, UK
- **Nick Lemoine**  
Barts and The London School of Medicine and Dentistry, UK
- **Simon Vincent**  
Cancer Research UK, London, UK

## Grant-writing workshop – Sponsored by Elsevier

14.00 – 15.00

Hosted by David Critchley

Cancer Research UK, London, UK

- **Liz Simpson**  
Imperial College School of Medicine, UK
- **Margaret Frame**  
Beatson Institute for Cancer Research, Glasgow, UK



## PhD Students' careers workshop –

### Finding a Post Doc position

Sponsored by Aegera

14.00 – 15.00

Hosted by Sally Leever

CR-UK London Research Institute, UK





- **Alison Lloyd**  
MRC Laboratory for Molecular Cell Biology, University College London, UK
- **Sir David Lane**  
Institute of Molecular and Cell Biology, Singapore
- **Birgit Lane**  
Centre for Molecular Medicine, Singapore and University of Dundee, UK

### Post Docs' careers workshop – Sponsored by Aegera

14.00 – 15.00

Hosted by Caroline Dive

Paterson Institute for Cancer Research, UK

- **Keith Caldecott**  
University of Sussex, UK  
Independent Fellowship to Senior Scientist
- **Andrew Walker**  
AstraZeneca, UK  
Scientific Writing
- **Tanya Moore**  
Cancer Research Technology, UK  
Intellectual Property in Science
- **Kat Arney**  
Cancer Research UK, UK  
Scientific Journalism

Tuesday 10 October 2006

### BACR educational workshop - Imaging of cancer targets

08.00 – 08.50

- **Eric Aboagye**  
Imperial College London, UK
- **Kevin Francis**  
Xenogen, USA



### Commercial workshop Novel microarray approaches to studying genome architecture

Sponsored by Affymetrix

13.00 – 14.00

- **Bryan D Young**  
Bart's & The London School of Medicine, UK  
The use of Affymetrix GeneChip® Exon Arrays to investigate expression profiles in leukaemias



The objective of this workshop will be to demonstrate how ground-breaking discoveries in cancer research could be facilitated by the use of novel Affymetrix approaches to interrogate the genome. Recent advances in Affymetrix novel technologies for studying genome architecture will be discussed.

## Careers in radiation related research: clinical and scientific – Organised by the Academic Clinical Oncology and Radiobiology Research Network (ACORRN)

14.00 – 15.00

Hosted by Pat Price

University of Manchester and ACORRN Steering Committee, UK

- **Gillian Heap**  
University of Manchester, UK
- **Catharine West**  
University of Manchester, UK
- **Cath Holborn**  
Sheffield Hallam University, UK
- **Mary Tanay**  
Royal Marsden Hospital, London, UK
- **Pat Price**  
University of Manchester and ACORRN Steering Committee, UK

## Women in science

14.00 – 15.00

Hosted by Clare Isacke

Breakthrough Breast Cancer Research Centre, UK

- **Ava Yeo**  
CR-UK London Research Institute, UK
- **Inke Näthke**  
University of Dundee, UK
- **Liz Simpson**  
Imperial College School of Medicine, UK
- **Fiona Hemsley**  
Cancer Research UK, UK

Wednesday 11 October 2006

## Thrombosis and cancer workshop

13.00 – 15.00

Chaired by Rob Coleman and Rob Carpenter

University of Sheffield, Weston Park Hospital, UK and Barts and The London, UK

- **Annie Young**  
3 Counties Cancer Network, UK  
Catheters and thrombosis: practical management
- **John Pasi**  
Institute of Cell and Molecular Science, Bart's and The London Medical  
School, UK  
Managing anticoagulation in the cancer patient
- **Ajay Akkar**  
Queen Mary's School of Medicine and Dentistry, London, UK  
Preventing venous thromboembolism in the cancer patient